2023-04-17 06:41:26 ET
- Amneal Pharmaceuticals ( NYSE: AMRX ) reports Q1 preliminary net revenue of $550 million to $560 million up 12% Y/Y against $529.36M consensus.
- Q1 loss before income taxes of $10M to $0, an improvement of ~50% Y/T.
- Adjusted EBITDA of $115M to $120M, up ~18% Y/Y.
- Long-term debt of $2.692B and cash and cash equivalents and restricted cash of $151M as of March 31, 2023, resulting in net debt of $2.541B as of March 31, 2023 compared to net debt of $2.647B as of December 31, 2022.
- The company re-affirms FY23 guidance of $2.25-$2.35B vs. $2.32B, Adj EBITDA of $500M-$530M, Adj. EPS of $0.40-$0.50 vs. $0.50 consensus.
- AMRX +3% premarket to $1.41
- Source: Press Release
For further details see:
Amneal pops 3% after early look at Q1 results, re-affirms FY23 guidance